Imaging of Hepatocellular Carcinoma: Qualitative and Quantitative Analysis of Postvascular Phase Contrast-Enhanced Ultrasonography with Sonazoid
Tatsuo Inoue, Kiyoshi Maekawa(Kindai University), Masatoshi Kudo(Kindai University), Satoshi Kitai(Kindai University), Yasunori Minami, Kazuomi Ueshima(Kindai University), Satoru Hagiwara(Kindai University Hospital), Syunsuke Takahashi, Emi Ishikawa(Kyowa Chemical Industry (Japan)), Taisuke Ueda(Kindai University), Kinuyo Hatanaka(Union Hospital), Hobyung Chung(Kindai University)
Cited by 40
Related Papers
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
|Journal of Clinical Oncology|2019|1.8k
Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma
|NEJM Evidence|2022|1.4k
Global patterns of hepatocellular carcinoma management from diagnosis to death: the <scp>BRIDGE</scp> Study
|Liver International|2015|1.3k